NEJM This Week NEJM This Week — September 18, 2025
21 snips
Sep 17, 2025 Discover new insights into PI3K-altered colorectal cancer, where low-dose aspirin may reduce recurrence. Explore groundbreaking diabetes therapies like oral semaglutide that promise better weight control. Delve into ventilation techniques comparing PAV+ and PSV modes. A pediatric case highlights the complexities of tumor lysis syndrome. Plus, gain perspectives on integrating pharmacotherapy in tobacco control and evaluating ultra-processed foods within public health policies.
AI Snips
Chapters
Transcript
Episode notes
PI3K Testing Changes Adjuvant Care
- Testing tumors for PIK3CA and related PI3K pathway mutations should occur soon after colorectal-cancer diagnosis.
- Prescribing low-dose aspirin postoperatively for patients with those mutations establishes a new adjuvant standard of care.
Orforglipron Mirrors Peptidic GLP-1 Effects
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, improved HbA1c and produced major weight loss in early type 2 diabetes.
- Gastrointestinal side effects were typical and no clear hepatotoxicity appeared in this trial.
25 mg Oral Semaglutide Is Effective
- Oral semaglutide 25 mg produced substantial weight loss in adults with overweight or obesity without diabetes.
- Its safety profile matched expectations for the GLP-1–agonist class.